share_log

Truist Securities Downgrades TCR2 Therapeutics to Hold, Lowers Price Target to $3

Benzinga ·  Mar 8, 2023 09:45

Truist Securities analyst Asthika Goonewardene downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Hold and lowers the price target from $8 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment